How it works:
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It delays gastric emptying, reduces appetite, enhances insulin secretion and decreases glucagon release, resulting in better blood glucose control and weight reduction.
Recommended for:
Clinical studies:
Trials have demonstrated Liraglutide leads to 8–12% average weight loss with long-term use and significantly improves HbA1c and reduces cardiovascular risk in diabetic patients.
The medicine is administered subcutaneously once daily into the abdomen, thigh or upper arm. Dosage is determined individually by a healthcare professional based on tolerance and therapeutic response.
Contraindications:
Side effects:
